CD22 Antibody (RFB-4): sc-7307

CD22 Antibody (RFB-4) is a mouse monoclonal IgG1 antibody that detects CD22 in human samples through immunofluorescence (IF) and flow cytometry (FCM) applications. CD22 is a critical B lymphocyte-specific antigen, also known as B-lymphocyte cell adhesion molecule (BLCAM), sialic acid-binding Ig-like lectin 2 (Siglec-2), and Leu-14. This type I integral membrane glycoprotein plays a vital role in regulating B cell signaling, which is essential for proper immune responses. CD22 is expressed in both cytoplasmic and membrane forms during various stages of B cell differentiation; the cytoplasmic variant is particularly significant as a marker for acute lymphocytic leukemia, while the membrane form is present in mature B cells before differentiation into plasma cells. Alternative splicing of the CD22 gene results in two isoforms, CD22α and CD22β, with CD22β being the predominant form. CD22 can exist as a heterodimer composed of CD22β and the shorter isoform, CD22α, highlighting the complexity of its structure and potential for diverse functional interactions within the immune system. Anti-CD22 antibody (RFB-4) is an invaluable tool for researchers studying B cell biology and related pathologies.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

CD22 Antibody (RFB-4) References:

1. CD22 blockade restores homeostatic microglial phagocytosis in ageing brains.  |  Pluvinage, JV., et al. 2019. Nature. 568: 187-192. PMID: 30944478
2. Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation.  |  Liu, S., et al. 2021. Am J Hematol. 96: 671-679. PMID: 33725422
3. Trispecific CD19-CD20-CD22-targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models.  |  Schneider, D., et al. 2021. Sci Transl Med. 13: PMID: 33762438
4. Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells.  |  Singh, N., et al. 2021. Nat Med. 27: 842-850. PMID: 33888899
5. CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial.  |  Spiegel, JY., et al. 2021. Nat Med. 27: 1419-1431. PMID: 34312556
6. Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells.  |  Lichtenstein, DA., et al. 2021. Blood. 138: 2469-2484. PMID: 34525183
7. A novel CD19/CD22/CD3 trispecific antibody enhances therapeutic efficacy and overcomes immune escape against B-ALL.  |  Zhao, L., et al. 2022. Blood. 140: 1790-1802. PMID: 35981465
8. CD22-targeted CD28 bispecific antibody enhances antitumor efficacy of odronextamab in refractory diffuse large B cell lymphoma models.  |  Wei, J., et al. 2022. Sci Transl Med. 14: eabn1082. PMID: 36350988
9. CD22 blockade modulates microglia activity to suppress neuroinflammation following intracerebral hemorrhage.  |  Ren, H., et al. 2023. Pharmacol Res. 196: 106912. PMID: 37696483
10. Targeting CD22 for B-cell hematologic malignancies.  |  Xu, J., et al. 2023. Exp Hematol Oncol. 12: 90. PMID: 37821931

The preferred CD22 antibody is CD22 Antibody (D-5): sc-271579.